GlobeNewswire

Segment Launches New End-User Privacy Tools that Streamline and Simplify GDPR Compliance Across Segment and Supported Partners

Dela

The Leading Customer Data Platform Helps Companies Manage User Deletion Requests; Automatically Forwards Requests to Supported Integrations

SAN FRANCISCO, April 24, 2018 (GLOBE NEWSWIRE) -- Segment, the customer data platform, today announced the availability of new product features that will help brands achieve compliance with the European Union's General Data Protection Regulation (GDPR), which takes effect May 25, 2018. Using either a simple user interface or an API, Segment customers will be able to manage user deletion and suppression requests, as well as automatically forward them to supported Segment integrations such as Amplitude, Braze (formerly Appboy), Intercom and Iterable. With these new features, Segment helps its customers meet key end-user rights requests under the GDPR.

"We welcome the GDPR because it sets a new standard for privacy rights, requiring businesses to be more transparent about how they use their customers' personal data," said Peter Reinhardt, co-founder and CEO of Segment. "Segment has always been committed to building a customer data platform that is respectful of user privacy and powered by first-party data. We are dedicated not only to helping our customers achieve GDPR compliance, but also to fostering a partner ecosystem that is privacy-conscious and prioritizes the rights of the individual."

Under the GDPR, consumer rights are strengthened and expanded, and end-user rights requests are likely to increase given the recent widespread interest in consumer privacy. While the GDPR will raise the bar for protecting end-users' rights and privacy, it presents a complex technological challenge for most companies - evidenced by a Gartner estimate that more than 50 percent of companies affected by the GDPR will not be in full compliance by the time the law goes into effect.

Streamline Compliance with GDPR Rights Requests

With Segment, brands will be able to operationalize GDPR rights requests through a new, simple user interface or a new API. Specifically, companies will be able to:

  • Issue deletion requests to delete a specified user's data from Segment. Data will be deleted where it is stored on the Segment platform.
  • Issue deletion requests to delete user data from supported integrations. Issuing a delete call will also delete a user's data from Amazon Redshift, Amazon S3, Google BigQuery and Postgres.
  • Forward user deletion requests to supported integrations. Segment automatically forwards deletion requests to supported integrations, like Amplitude, Braze (formerly Appboy), Intercom and Iterable.
  • Suppress data collection for specific users. Add users to a suppression list to restrict user data from being sent to Segment and supported integrations.
  • Monitor deletion and suppression status from a user interface. To help with monitoring and auditing rights requests, all user deletion and suppression requests will be documented within Segment.

In addition, Segment's existing functionality already supports:

  • Honoring the rights to access and portability. Segment's raw data integrations and warehouses enable companies to compile a complete picture of all data sent to Segment about a user and share it with them in a structured format.
  • Rectifying user data. With just a single API call, companies can create or update a user's data inside of Segment and across a company's connected integrations, ensuring a user's data is always up-to-date.

"Amplitude and Segment share a similar mission. We want to help companies build great products, engage their customers and grow their business," said Spenser Skates, CEO of Amplitude. "We are delighted to announce that we have further strengthened this partnership. We are working together to prioritize and simplify user privacy for all."

"Braze (formerly Appboy) is committed to ongoing compliance with the GDPR, serving as good stewards of our clients' data, and promoting seamless data connections between our partners," said Bill Magnuson, CEO and co-founder of Braze (formerly Appboy). "Working in partnership with Segment to streamline and simplify end-user requests helps us to accomplish these goals, while also supporting brands as they work toward compliance with the GDPR."

About Segment
Segment is the infrastructure for your customer data. Use one API to unlock 200+ tools for every team in your company. With Segment, developers can stop building tedious and expensive one-off data integrations while business users can compute important traits about each customer and push this data to their favorite apps for analytics and personalization. Segment is trusted by thousands of companies including Gap Inc., New Relic, Instacart, Intuit, and Time. For more information visit https://segment. com.

Danielle Stickler
segment@bateman-group.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Segment via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum